REG - Haleon PLC - Final prospectus supplement filed with the SEC

HALEONAnnouncement

20/03/2024 08:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240320:nRST5877Ha&default-theme=true

RNS Number : 5877H  Haleon PLC  20 March 2024

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE
OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE
A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

 

Haleon plc: Final prospectus supplement filed with the SEC

 

20 March 2024: On 19 March 2024, Haleon plc ("Haleon") filed with the United
States Securities and Exchange Commission (the "SEC") a final prospectus
supplement to the shelf registration statement on Form F-3 filed by Haleon on
3 July 2023. The preliminary prospectus supplement has been submitted to the
National Storage Mechanism and is available on the SEC's website at
https://www.sec.gov/Archives/edgar/data/1900304/000110465924036189/tm248861-4_424b1.htm
(https://url.de.m.mimecastprotect.com/s/6DkPCPjnR4InQqGWSzVi--?domain=sec.gov)
.

 

This announcement shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of securities in any state or
other jurisdiction in which, or to any person to whom, such an offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or other jurisdiction. The
distribution or communication of this announcement or the prospectus
supplement in certain jurisdictions may be restricted by law. Any offer may be
withdrawn or revoked, without obligation or commitment of any kind, at any
time prior to notice of its acceptance given after the effective date.

 

 Enquiries

 Investors                                                                       Media

 Sonya Ghobrial                          +44 7392 784784                         Zoë Bird                             +44 7736 746167
 Rakesh Patel                            +44 7552 484646                         Nidaa Lone                           +44 7841 400607
 Emma White                              +44 7792 750133

 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)     Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

The person responsible for arranging the release of this announcement on
behalf of Haleon is Amanda Mellor, Company Secretary.

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

In the United Kingdom, this announcement and its contents are directed only at
(A) "qualified investors" within the meaning of Article 2(e) of Regulation
(EU) 2017/1129 (as

amended) as it forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018; and (B) (i) persons who have professional experience in
matters relating to investments falling within Article 19 of the UK Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"),
or (ii) high net worth entities and other persons to whom it can otherwise
lawfully be communicated falling within Article 49(2)(a) to (d) of the Order,
all such persons in (A) and (B) together being referred to as "relevant
persons". This announcement must not be acted on or relied on in the United
Kingdom by persons who are not relevant persons. Any investment activity to
which this announcement relates is available in the United Kingdom only to
relevant persons and will be engaged in only with relevant persons.

 

In the European Economic Area (the "EEA"), this announcement is addressed only
to and directed only at, persons in member states who are "qualified
investors" within the meaning of Article 2(e) of Regulation (EU) 2017/1129 (as
amended) ("Qualified Investors"). This announcement must not be acted on or
relied on in the EEA by persons who are not Qualified Investors. Any
investment activity to which this announcement relates is available in the EEA
only to Qualified Investors and will be engaged in only with Qualified
Investors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PSPGIGDXRXDDGSG